Syschem
51.41
+0.17(+0.33%)
Market Cap₹223.74 Cr
PE Ratio27.11
IndustryHealthcare
Company Performance:
1D+0.33%
1M+3.92%
6M+10.56%
1Y+14.19%
5Y+566.80%
View Company Insightsright
More news about Syschem
11Nov 25
Syschem India Reports Net Loss of Rs 60.54 Crore in Q2 FY2026
Syschem (India) Limited announced unaudited financial results for Q2 FY2026, reporting a net loss of Rs 60.54 crore, compared to a profit of Rs 67.18 crore in the previous quarter. Revenue from operations decreased to Rs 1,179.24 crore from Rs 1,267.58 crore. For the half-year ending September 30, 2025, the company recorded a loss of Rs 422.07 crore before tax. Total assets stood at Rs 2,172.62 crore, with total equity at Rs 948.60 crore. Trade receivables and inventories decreased to Rs 697.03 crore and Rs 413.24 crore respectively.
 no imag found
22Oct 25
Syschem India Settles ₹5.18 Crore Legal Case with QP Pharmachem
Syschem India Limited has resolved a legal dispute with QP Pharmachem, involving a total settlement of ₹5.18 crore. The case, filed under Section 138 of the Negotiable Instruments Act, has been dismissed as withdrawn. Syschem has already paid ₹3.95 crore, with a contingent payment of ₹1.23 crore issued as a cheque. This contingent amount is subject to potential dollar exchange rate differences for remittance to a Chinese entity. The settlement order was received on October 22, 2025, from the Chief Judicial Magistrate - 1st Class, Taluka Court, Derabassi.
 no imag found
29Sept 25
Syschem (India) Unveils Ambitious Expansion Plan for Antibiotic Production
Syschem (India) Limited announces significant expansion of its antibiotic production capabilities. The company's board has approved plans for a new factory to produce Cloxacillin, Dicloxacillin, and Flucloxacillin Sodium, as well as the expansion of its existing amoxicillin unit. The total investment is estimated at Rs. 15.00 to 20.00 Crore, financed through internal accruals or debt funding. The expansion will add 1,600.00 TPA to the current plant capacity of 2,400.00 TPA. The project is expected to be completed by December 2025, aiming to improve operational efficiency, strengthen product portfolio, and meet growing customer demand.
 no imag found
12Sept 25
Syschem (India) Limited Wins Litigation Case, Faces Rs 15.00 Lakh Financial Impact
Syschem (India) Limited, a BSE-listed company, has successfully concluded a legal case filed by Shri Shubham Road Carer. The City Civil Court in Secunderabad dismissed the suit as the plaintiff filed a memo stating it was not being pursued. Despite the favorable outcome, Syschem faces a total financial impact of Rs 15 lakh, comprising Rs 9,14,545 as principal amount and Rs 5,85,455 in litigation costs and interest. The company has duly informed BSE Limited about the case's disposal in compliance with SEBI regulations.
 no imag found
04Aug 25
Syschem India Reports 24% Revenue Growth in Q1, Expands Production Capacity
Syschem India Limited reported robust Q1 results with total income reaching ₹126.76 crore, a 24% increase year-over-year. Profit before tax surged by 1124% to ₹1.67 crore. The company achieved an 81% increase in production capacity and is constructing a new WHO-GMP compliant manufacturing unit in Kalka, Haryana. Syschem has expanded its presence across 12 Indian states and several international markets. The board made key appointments to strengthen corporate governance and granted stock options to key employees.
 no imag found
Syschem
51.41
+0.17
(+0.33%)
1 Year Returns:+14.19%
Industry Peers
Sun Pharmaceutical
1,724.40
(+0.64%)
Divis Laboratories
6,291.00
(-0.10%)
Torrent Pharmaceuticals
4,241.70
(+0.36%)
Cipla
1,341.10
(+0.92%)
Dr Reddys Laboratories
1,280.40
(-0.15%)
Lupin
2,219.40
(-0.42%)
Zydus Life Science
900.75
(-0.18%)
Mankind Pharma
2,024.30
(-0.75%)
Aurobindo Pharma
1,158.80
(-1.08%)
Alkem Laboratories
5,392.00
(+0.28%)